{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:38:08Z","timestamp":1777934288374,"version":"3.51.4"},"reference-count":11,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T00:00:00Z","timestamp":1505433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:p>\n                    Carfilzomib is a second-generation proteasome inhibitor that irreversibly inhibits chymotrypsin-like (CT-L) activities of the proteasome, and is indicated for relapsed or refractory multiple myeloma. Cardiotoxicity is a well-established adverse effect of carfilzomib. The extent of cardiac toxicity in the literature spans anywhere from palpitations to cardiac arrest, with the most commonly reported manifestation being new-onset or worsening heart failure. A pre-clinical study of the pharmacokinetics and pharmacodynamics of carfilzomib given via intravenous bolus or 30-minute infusion in rats showed that carfilzomib can strongly induce apoptosis and potently damage cardiac myocytes at clinically relevant concentrations. Moreover, the mortality rate with the bolus administration was 44% whereas the same dose administered as a 30-minute infusion did not result in mortality. There remains limited clinical data regarding the safety of carfilzomib at doses of 27\u201356\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    based on infusion times as these doses have not been well studied. This retrospective review was conducted to evaluate the safety of carfilzomib at doses &gt;27\u2009mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    at all infusion times.\n                  <\/jats:p>","DOI":"10.1177\/1078155217729564","type":"journal-article","created":{"date-parts":[[2017,9,15]],"date-time":"2017-09-15T06:16:43Z","timestamp":1505456203000},"page":"229-233","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":4,"title":["Cardiotoxicity with carfilzomib at doses greater than 27\u2009mg\/m\n                    <sup>2<\/sup>\n                    : A case series"],"prefix":"10.1177","volume":"25","author":[{"given":"Gee Youn","family":"Kim","sequence":"first","affiliation":[{"name":"Department of Pharmacy, New York University Langone Medical Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania","family":"Ahuja","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, New York University Langone Medical Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Papadopoulos","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, New York University Langone Medical Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Cirrone","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, New York University Langone Medical Center, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,9,15]]},"reference":[{"key":"bibr1-1078155217729564","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-10-459883"},{"key":"bibr2-1078155217729564","unstructured":"Kyprolis\u00ae (package insert). Thousand Oaks, CA: Onyx Pharmaceuticals, Inc., 2016."},{"key":"bibr3-1078155217729564","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.039164"},{"key":"bibr4-1078155217729564","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2013.089334"},{"key":"bibr5-1078155217729564","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00464-7"},{"key":"bibr6-1078155217729564","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2014.93"},{"key":"bibr7-1078155217729564","doi-asserted-by":"crossref","unstructured":"Hasinoff BB, Patel D and Wu X. Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib.\n                      Cardiovasc Toxicol\n                      2017; 17: 237\u2013250.","DOI":"10.1007\/s12012-016-9378-7"},{"key":"bibr8-1078155217729564","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.3522"},{"key":"bibr9-1078155217729564","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154"},{"key":"bibr10-1078155217729564","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12677"},{"key":"bibr11-1078155217729564","doi-asserted-by":"publisher","DOI":"10.1186\/2162-3619-1-10"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217729564","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217729564","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217729564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:38Z","timestamp":1777688258000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217729564"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,15]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["10.1177\/1078155217729564"],"URL":"https:\/\/doi.org\/10.1177\/1078155217729564","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,15]]}}}